Table F10Dementia—active controlled trials versus SRI

SRIAtypicals
Adverse EventsDrug# of studies# adverse eventssample size# adverse eventssample sizePooled OR95% CI
Cardiovascular/BP/DecreaseRisperidone1053150+Inf(0.03, Inf+ )
Constitutional/Fever or InfectionRisperidone1053250+Inf(0.20, Inf+ )
EndocrineRisperidone11530500.00(0.00, 41.34)
GastrointestinalRisperidone11532502.15(0.11, 130.24)
InfectionsRisperidone12530500.00(0.00, 5.63)
Liver Function Test AbnormalityRisperidone1053150+Inf(0.03, Inf+ )
NeuroRisperidone11530500.00(0.00, 41.34)
Neuro/Movement Disorder/EPSRisperidone11533503.28(0.25, 177.53)
Neuro/Movement Disorder/GaitRisperidone11533503.28(0.25, 177.53)
Neuro/SedationRisperidone11530500.00(0.00, 41.34)
Psychiatric/AgitationRisperidone112537500.56(0.17, 1.72)
Psychiatric/DepressionRisperidone11530500.00(0.00, 41.34)
Psychiatric/PsychoticRisperidone11531501.06(0.01, 84.88)
Psychiatric/SeriousRisperidone12533501.62(0.18, 20.19)
Psychiatric/Suicide AttemptRisperidone1053150+Inf(0.03, Inf+ )
TraumaRisperidone11530500.00(0.00, 41.34)

CI = confidence interval; OR = odds ratio

From: Appendix F, Adverse Events Analyses

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.